Catalysts for $ABBV
478 tracked
Dec 18, 2025
approval
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) โ FDA approval
CARIPRAZINE HYDROCHLORIDE
โ
Dec 18, 2025
approval
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) โ FDA approval
CARIPRAZINE HYDROCHLORIDE
โ
Dec 18, 2025
approval
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) โ FDA approval
CARIPRAZINE HYDROCHLORIDE
โ
Dec 18, 2025
approval
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) โ FDA approval
CARIPRAZINE HYDROCHLORIDE
โ
Dec 17, 2025
approval
ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE) โ FDA approval
ORIAHNN (COPACKAGED)
โ
Dec 17, 2025
approval
ORILISSA (ELAGOLIX SODIUM) โ FDA approval
elagolix sodium
โ
Nov 26, 2025
recall
Imprimis NJOF, LLC recall (Cls III)
AbbVie Inc.
โ
Nov 25, 2025
approval
PRED MILD (PREDNISOLONE ACETATE) โ FDA approval
prednisolone acetate
โ
Nov 4, 2025
approval
LINZESS (LINACLOTIDE) โ FDA approval
linaclotide
โ
Oct 21, 2025
approval
IMBRUVICA (IBRUTINIB) โ FDA approval
AbbVie Inc.
โ
Oct 21, 2025
approval
IMBRUVICA (IBRUTINIB) โ FDA approval
AbbVie Inc.
โ
Oct 21, 2025
approval
IMBRUVICA (IBRUTINIB) โ FDA approval
AbbVie Inc.
โ
Oct 10, 2025
approval
RINVOQ (UPADACITINIB) โ FDA approval
upadacitinib tartrate ER
โ
Oct 10, 2025
approval
RINVOQ LQ (UPADACITINIB) โ FDA approval
upadacitinib
โ
Oct 9, 2025
approval
ESCITALOPRAM OXALATE โ FDA approval
AbbVie Inc.
โ
Sep 30, 2025
approval
QULIPTA (ATOGEPANT) โ FDA approval
atogepant
โ
Sep 3, 2025
approval
SKYRIZI (RISANKIZUMAB-RZAA) โ FDA approval
risankizumab
โ
Sep 3, 2025
approval
SKYRIZI (RISANKIZUMAB-RZAA) โ FDA approval
risankizumab
โ
Aug 12, 2025
approval
RINVOQ (UPADACITINIB) โ FDA approval
upadacitinib tartrate ER
โ
Jul 16, 2025
approval
HUMIRA (ADALIMUMAB) โ FDA approval
adalimumab
โ
Jun 10, 2025
approval
QULIPTA (ATOGEPANT) โ FDA approval
atogepant
โ
Jun 10, 2025
approval
QULIPTA (ATOGEPANT) โ FDA approval
atogepant
โ
May 7, 2025
approval
SKYRIZI (RISANKIZUMAB-RZAA) โ FDA approval
risankizumab
โ
May 7, 2025
approval
SKYRIZI (RISANKIZUMAB-RZAA) โ FDA approval
risankizumab
โ
May 1, 2025
approval
DEPAKOTE (DIVALPROEX SODIUM) โ FDA approval
divalproex sodium DR
โ
May 1, 2025
approval
DEPAKOTE ER (DIVALPROEX SODIUM) โ FDA approval
divalproex sodium DR
โ
May 1, 2025
approval
DEPAKOTE (DIVALPROEX SODIUM) โ FDA approval
divalproex sodium DR
โ
Apr 28, 2025
approval
RINVOQ (UPADACITINIB) โ FDA approval
upadacitinib tartrate ER
โ
Mar 26, 2025
approval
RINVOQ (UPADACITINIB) โ FDA approval
upadacitinib tartrate ER
โ
Mar 26, 2025
approval
RINVOQ LQ (UPADACITINIB) โ FDA approval
upadacitinib
โ